Table 3 Univariate and multivariate time‐to‐event analysis of baseline and therapy characteristics.

From: Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy

Parameters

P-value

HR

HR 95% CI

Under

Upper

Univariate analysis

Age

0.186

0.984

0.961

1.008

Female gender

0.593

0.857

0.485

1.512

Localization of tumor

0.127

1.595

0.875

2.904

M1

0.019

1.941

1.113

3.383

Histological grading

0.644

1.067

0.811

1.403

Albumin

0.042

0.958

0.919

0.998

CRP

0.130

1.006

0.998

1.015

gGT

0.081

1.000

1.000

1.001

Alanine aminotransferase

0.237

1.002

0.999

1.005

Aspartate aminotransferase

0.834

1.001

0.996

1.005

CA19-9

0.142

1.000

1.000

1.000

ECOG at diagnosis

0.051

1.436

0.999

2.063

MELD score

0.257

1.036

0.974

1.103

eRFA + CT

0.005

0.438

0.248

0.775

Photodynamic therapy

0.875

0.955

0.536

1.701

No surgery

0.256

1.378

0.792

2.398

Primary surgery with tumor resection

0.059

0.461

0.207

1.029

Primary surgery without tumor resection

0.967

0.988

0.558

1.750

PTCD

0.416

1.303

0.688

2.467

Multivariate analysis

eRFA + CT

0.010

0.422

0.218

0.816

Primary surgery with tumor resection

0.004

0.201

0.068

0.596

  1. CA19-9 carbohydrate antigen 19-9, CRP C-reactive protein, CT chemotherapy, ECOG Eastern Cooperative Oncology Group performance status, eRFA endobiliary radiofrequency ablation, gGT gamma-glutamyltransferase, MELD score model of end stage liver disease score, PTCD percutaneous transhepatic bile duct drainage.
Back to article page